Grifols: Morgan Stanley positive ahead of Alzheimer data

(CercleFinance.com) - Morgan Stanley maintains its "overweight" rating on Grifols, with a target price of 35 euros, seeing the announcement of Alzheimer's trial data next month as a potential catalyst for the share.


In a note to clients, the broker says that the Spanish life science company will present complete data from its Alzheimer's phase 2b/3 trial on 6 December, including biomarker and neuroimaging results.

"We see the base case skewed to the upside with Grifols already committed to further trials," it wrote in the note.

Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.